EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access

Increased Synthetic Cytotoxicity of Combinatorial Chemoradiation Therapy in Homologous Recombination Deficient Tumors

Jennifer Ma, Rachna Shah, Andrew C Bell, Niamh McDermott, Xin Pei, Pier Selenica, Justin Haseltine, Robert Delsite, Atif J Khan, Benjamin H Lok, Matthew J Ellis, Rebecca F Aft und 4 weitere

International Journal of Radiation Oncology*Biology*Physics · 2025

DOI: 10.1016/j.ijrobp.2024.06.037 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2025. Verfasst von Jennifer Ma und 15 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. Hauptthemen laut MEDLINE: Homologous Recombination, Triple Negative Breast Neoplasms, Chemoradiotherapy, Breast Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Homologous recombination deficient (HRD) tumors are exquisitely sensitive to platinum-based chemotherapy and when combined with radiation therapy (RT), leads to improved overall survival in multiple cancer types. Whether a subset of tumors with distinct molecular characteristics demonstrate increased benefit from cisplatin and RT (c-RT) is unclear. We hypothesized that HRD tumors, whether associated with BRCA mutations or genomic scars of HRD, exhibit exquisite sensitivity to c-RT, and that HRD may be a significant driver of c-RT benefit. METHODS AND MATERIALS: Sensitivity to c-RT was examined using isogenic and sporadic breast cancer cell lines. HRD was assessed using 4 assays: RT-induced Rad51 foci, a DR-GFP reporter assay, a genomic scar score (large-scale state transitions [LST]), and clonogenic survival assays. Whole-genome sequencing of 4 breast tumors from a phase 2 clinical trial of neoadjuvant c-RT in triple-negative breast cancer was performed and HRD was defined using HRDetect. RESULTS: BRCA1/2 deficient cell lines displayed functional HRD based on the Rad51 functional assay, with c-RT to RT or cisplatin interaction ratios (IR) of 1.11 and 26.84 for the BRCA1 isogenic pair at 2 μM cisplatin and 6 Gy, respectively. The highest LST lines demonstrated HRD and synthetic cytotoxicity to c-RT with IR at 2 Gy and cisplatin 20 μM of 7.50, and the lowest LST line with IR of 0.65. Of 4 evaluable patients in the phase 2 trial, one achieved a pathologic complete response with corresponding HRD based on multiple genomic scar scores including HRDetect and LST scores, compared with patients without a pathologic complete response. CONCLUSIONS: HRD breast cancers, whether identified by BRCA1/2 mutation status, functional tests, or mutational signatures, appear to be significantly more sensitive to c-RT compared with isogenic controls or tumors without HRD mutational signatures. HRD tumors may be exquisitely sensitive to c-RT which warrants further clinical investigation to guide a precision oncology approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Homologous RecombinationTriple Negative Breast NeoplasmsChemoradiotherapyBreast NeoplasmsRadiation ToleranceHumansCisplatinFemaleCell Line, TumorRad51 RecombinaseBRCA2 ProteinMutationBRCA1 ProteinAntineoplastic Agents

Substanzen

CisplatinRad51 RecombinaseRAD51 protein, humanBRCA2 ProteinBRCA1 ProteinAntineoplastic Agents

Autor:innen und Institutionen

  • Departments of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Departments of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York; Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; Department…
  • Department of Medicine, Baylor College of Medicine, Houston, Texas.
  • Department of General Surgery, Washington University, St Louis, Missouri.
  • Departments of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: riazn@mskcc.org.

Förderung

  • NCI NIH HHS

Zitieren

APA

Ma, J., Shah, R., Bell, A. C., McDermott, N., Pei, X., Selenica, P., Haseltine, J., Delsite, R., Khan, A. J., Lok, B. H., Ellis, M. J., Aft, R. F., Setton, J., Reis-Filho, J. S., Riaz, N., & Powell, S. N. (2025). Increased Synthetic Cytotoxicity of Combinatorial Chemoradiation Therapy in Homologous Recombination Deficient Tumors. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2024.06.037

Vancouver

Ma J, Shah R, Bell AC, McDermott N, Pei X, Selenica P, et al. Increased Synthetic Cytotoxicity of Combinatorial Chemoradiation Therapy in Homologous Recombination Deficient Tumors. International Journal of Radiation Oncology*Biology*Physics. 2025. doi:10.1016/j.ijrobp.2024.06.037

BibTeX
@article{Ma2025,
  author = {Ma, Jennifer and Shah, Rachna and Bell, Andrew C and McDermott, Niamh and Pei, Xin and Selenica, Pier and Haseltine, Justin and Delsite, Robert and Khan, Atif J and Lok, Benjamin H and Ellis, Matthew J and Aft, Rebecca F and Setton, Jeremy and Reis-Filho, Jorge S and Riaz, Nadeem and Powell, Simon N},
  title = {Increased Synthetic Cytotoxicity of Combinatorial Chemoradiation Therapy in Homologous Recombination Deficient Tumors},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2025},
  doi = {10.1016/j.ijrobp.2024.06.037}
}
Kostenlos starten →